← Back to Clinical Trials
Recruiting NCT06411561

NCT06411561 A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06411561
Status Recruiting
Phase
Sponsor University of Washington
Condition Critical Illness
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-12-26
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
SLEEP + COGCOGSLEEP

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-12-26 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which contribute to higher risk for cognitive decline related to Alzheimer's disease and related dementias. Sleep and activity are essential for recovery from critical illness, yet ICU survivors experience both sleep deficiency and profound inactivity. About 75-80% of ICU patients experience circadian dysrhythmia, which contributes to cognitive decline and increases likelihood of developing Alzheimer's disease and related dementias. The scientific premises of the proposed study are: 1) a combined sleep promotion and cognitive training intervention will have synergistic effects to mitigate the risk of cognitive impairment and development of Alzheimer's disease and related dementias in older ICU survivors; and 2) chronotherapeutic timing of interventions (i.e., adjusting timing of interventions according to circadian rhythm) may improve intervention efficacy.

Eligibility Criteria

Inclusion Criteria: * Age greater than or equal to 60 years old * Current hospitalization at University of Washington Medical Center or Harborview Medical Center * Intensive care unit (ICU) length of stay greater than 24 hours * Recovery from critical care status to acute care status, and/or discharge out of ICU * Fluent in English or Spanish * Functional independence on activities of daily living prior to hospitalization (Katz Index = 6) Exclusion Criteria: * Documented history or suspicion of Alzheimer's disease or dementia, or current prescription of anti-dementia medication * Documented history of bipolar disorder or schizophrenia * Documented acute stroke or traumatic brain injury * Severe vision impairment * Severe hearing impairment * Severe paralysis or dominant arm paresis * Transfer from skilled nursing care facility or inpatient rehabilitation facility

Contact & Investigator

Central Contact

Maya N Elias, PhD, MA, RN

✉ mnelias@uw.edu

📞 206-543-8564

Principal Investigator

Maya N Elias, PhD, MA, RN

PRINCIPAL INVESTIGATOR

University of Washington

Frequently Asked Questions

Who can join the NCT06411561 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06411561 currently recruiting?

Yes, NCT06411561 is actively recruiting participants. Contact the research team at mnelias@uw.edu for enrollment information.

Where is the NCT06411561 trial being conducted?

This trial is being conducted at Seattle, United States.

Who is sponsoring the NCT06411561 clinical trial?

NCT06411561 is sponsored by University of Washington. The principal investigator is Maya N Elias, PhD, MA, RN at University of Washington. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology